These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 25111319)
1. Structural biology of cisplatin complexes with cellular targets: the adduct with human copper chaperone atox1 in aqueous solution. Calandrini V; Nguyen TH; Arnesano F; Galliani A; Ippoliti E; Carloni P; Natile G Chemistry; 2014 Sep; 20(37):11719-25. PubMed ID: 25111319 [TBL] [Abstract][Full Text] [Related]
2. Interaction of cisplatin and analogue Pt(en)Cl2 with the copper metallo-chaperone Atox1. Sze CM; Shi Z; Khairallah GN; Feketeová L; O'Hair RA; Xiao Z; Donnelly PS; Wedd AG Metallomics; 2013 Aug; 5(8):946-54. PubMed ID: 23778981 [TBL] [Abstract][Full Text] [Related]
3. Oxidation of Human Copper Chaperone Atox1 and Disulfide Bond Cleavage by Cisplatin and Glutathione. Nardella MI; Rosato A; Belviso BD; Caliandro R; Natile G; Arnesano F Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500118 [TBL] [Abstract][Full Text] [Related]
4. Probing the interaction of cisplatin with the human copper chaperone Atox1 by solution and in-cell NMR spectroscopy. Arnesano F; Banci L; Bertini I; Felli IC; Losacco M; Natile G J Am Chem Soc; 2011 Nov; 133(45):18361-9. PubMed ID: 21981264 [TBL] [Abstract][Full Text] [Related]
5. Platination of the copper transporter ATP7A involved in anticancer drug resistance. Calandrini V; Arnesano F; Galliani A; Nguyen TH; Ippoliti E; Carloni P; Natile G Dalton Trans; 2014 Aug; 43(31):12085-94. PubMed ID: 24983998 [TBL] [Abstract][Full Text] [Related]
6. Copper binding modulates the platination of human copper chaperone Atox1 by antitumor trans-platinum complexes. Xi Z; Guo W; Tian C; Wang F; Liu Y Metallomics; 2014 Mar; 6(3):491-7. PubMed ID: 24469739 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro. Palm ME; Weise CF; Lundin C; Wingsle G; Nygren Y; Björn E; Naredi P; Wolf-Watz M; Wittung-Stafshede P Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6951-6. PubMed ID: 21482801 [TBL] [Abstract][Full Text] [Related]
8. Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1. Tian Y; Fang T; Yuan S; Zheng Y; Arnesano F; Natile G; Liu Y Metallomics; 2018 May; 10(5):745-750. PubMed ID: 29721562 [TBL] [Abstract][Full Text] [Related]
9. Crystal structures of cisplatin bound to a human copper chaperone. Boal AK; Rosenzweig AC J Am Chem Soc; 2009 Oct; 131(40):14196-7. PubMed ID: 19807176 [TBL] [Abstract][Full Text] [Related]
10. Determinants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijacking. Palm-Espling ME; Andersson CD; Björn E; Linusson A; Wittung-Stafshede P PLoS One; 2013; 8(7):e70473. PubMed ID: 23936210 [TBL] [Abstract][Full Text] [Related]
11. Copper binding promotes the interaction of cisplatin with human copper chaperone Atox1. Xi Z; Guo W; Tian C; Wang F; Liu Y Chem Commun (Camb); 2013 Dec; 49(95):11197-9. PubMed ID: 24150599 [TBL] [Abstract][Full Text] [Related]
12. Conserved residue modulates copper-binding properties through structural dynamics in human copper chaperone Atox1. Xi Z; Shi C; Tian C; Liu Y Metallomics; 2013 Nov; 5(11):1566-73. PubMed ID: 24056613 [TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric quantification of the binding ratio of metal-based anticancer complexes with protein thiols. Han Y; Guo W; Zheng W; Luo Q; Wu K; Zhao Y; Wang F Rapid Commun Mass Spectrom; 2019 May; 33(10):951-958. PubMed ID: 30812058 [TBL] [Abstract][Full Text] [Related]
14. The structural flexibility of the human copper chaperone Atox1: Insights from combined pulsed EPR studies and computations. Levy AR; Turgeman M; Gevorkyan-Aiapetov L; Ruthstein S Protein Sci; 2017 Aug; 26(8):1609-1618. PubMed ID: 28543811 [TBL] [Abstract][Full Text] [Related]
15. Identification of New Potential Interaction Partners for Human Cytoplasmic Copper Chaperone Atox1: Roles in Gene Regulation? Öhrvik H; Wittung-Stafshede P Int J Mol Sci; 2015 Jul; 16(8):16728-39. PubMed ID: 26213915 [TBL] [Abstract][Full Text] [Related]
16. Computational metallomics of the anticancer drug cisplatin. Calandrini V; Rossetti G; Arnesano F; Natile G; Carloni P J Inorg Biochem; 2015 Dec; 153():231-238. PubMed ID: 26490711 [TBL] [Abstract][Full Text] [Related]
17. Platinum transfer from hCTR1 to Atox1 is dependent on the type of platinum complex. Wu X; Yuan S; Wang E; Tong Y; Ma G; Wei K; Liu Y Metallomics; 2017 May; 9(5):546-555. PubMed ID: 28383086 [TBL] [Abstract][Full Text] [Related]
18. Reaction of platinum anticancer drugs and drug derivatives with a copper transporting protein, Atox1. Palm-Espling ME; Wittung-Stafshede P Biochem Pharmacol; 2012 Apr; 83(7):874-81. PubMed ID: 22285228 [TBL] [Abstract][Full Text] [Related]
19. Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs. Lasorsa A; Nardella MI; Rosato A; Mirabelli V; Caliandro R; Caliandro R; Natile G; Arnesano F J Am Chem Soc; 2019 Jul; 141(30):12109-12120. PubMed ID: 31283225 [TBL] [Abstract][Full Text] [Related]
20. Binding of Copper and Cisplatin to Atox1 Is Mediated by Glutathione through the Formation of Metal-Sulfur Clusters. Dolgova NV; Yu C; Cvitkovic JP; Hodak M; Nienaber KH; Summers KL; Cotelesage JJH; Bernholc J; Kaminski GA; Pickering IJ; George GN; Dmitriev OY Biochemistry; 2017 Jun; 56(24):3129-3141. PubMed ID: 28549213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]